Antibiotic treatment–induced secondary IgA deficiency enhances susceptibility to Pseudomonas aeruginosa pneumonia
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Broad-spectrum antibiotics are widely used with patients in intensive care units (ICUs), many of whom develop hospital-acquired infections with Pseudomonas aeruginosa. Although preceding antimicrobial therapy is known as a major risk factor for P. aeruginosa-induced pneumonia, the underlying mechanisms remain incompletely understood. Here we demonstrate that depletion of the resident microbiota by broad-spectrum antibiotic treatment inhibited TLR-dependent production of a proliferation-inducing ligand (APRIL), resulting in a secondary IgA deficiency in the lung in mice and human ICU patients. Microbiota-dependent local IgA contributed to early antibacterial defense against P. aeruginosa. Consequently, P. aeruginosa-binding IgA purified from lamina propria culture or IgA hybridomas enhanced resistance of antibiotic-treated mice to P. aeruginosa infection after transnasal substitute. Our study provides a mechanistic explanation for the well-documented risk of P. aeruginosa infection following antimicrobial therapy, and we propose local administration of IgA as a novel prophylactic strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43
Maslowski, K. M., Vieira, A. T., Ng, A., Kranich, J., Sierro, F., Yu, D., Schilter, H. C., Rolph, M. S., Mackay, F., Artis, D., et al. (2009) · Nature · doi:10.1038/nature08530 · Cited by 3,241 · cited 1×
“Indeed, we observed reduced levels of IgA (but not of IgM and IgG) in mice that were treated for 4 weeks with amoxicillin and clavulanate as compared with control mice (Figure 4, A and B, and our unpubcoupled receptor 43 (18), enhancing the antibacterial activity of neutrophils via NOD1 (19), priming inflammasome acti…”
BackgroundDevelopment of the Human Infant Intestinal Microbiota
Palmer, C., Bik, E. M., DiGiulio, D. B., Relman, D. A., & Brown, P. O. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050177 · Cited by 2,877 · cited 2×
“org Volume 128 Number 8 August 2018 GCAGCAG/TAMRA-3′) (56).”
BackgroundDethlefsen, L., & Relman, D. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000087107 · Cited by 2,421
The microbiota in adaptive immune homeostasis and disease
Honda, K., & Littman, D. R. (2016) · Nature · doi:10.1038/nature18848 · Cited by 1,846
Microbiota-mediated colonization resistance against intestinal pathogens
Buffie, C. G., & Pamer, E. G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3535 · Cited by 1,564 · cited 1×
“The microbiota mediates direct and indirect colonization resistance by outcompeting drug-resistant obligate or opportunistic pathogens and maintaining the local production of antibacterial peptides (15, 16).”
BackgroundMicrobiota regulates immune defense against respiratory tract influenza A virus infection
Ichinohe, T., Pang, I. K., Kumamoto, Y., Peaper, D. R., Ho, J. H., Murray, T. S., & Iwasaki, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019378108 · Cited by 1,502
Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity
Clarke, T. B., Davis, K. M., Lysenko, E. S., Zhou, A. Y., Yu, Y., & Weiser, J. N. (2010) · Nature Medicine · doi:10.1038/nm.2087 · Cited by 1,154 · cited 3×
“Indeed, we observed reduced levels of IgA (but not of IgM and IgG) in mice that were treated for 4 weeks with amoxicillin and clavulanate as compared with control mice (Figure 4, A and B, and our unpubcoupled receptor 43 (18), enhancing the antibacterial activity of neutrophils via NOD1 (19), priming inflammasome acti…”
BackgroundCommensal bacteria calibrate the activation threshold of innate antiviral immunity
Abt, M. C., Osborne, L. C., Monticelli, L. A., Doering, T. A., Alenghat, T., Sonnenberg, G. F., Paley, M. A., Antenus, M., Williams, K. L., Erikson, J., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.04.011 · Cited by 993 · cited 1×
“Indeed, we observed reduced levels of IgA (but not of IgM and IgG) in mice that were treated for 4 weeks with amoxicillin and clavulanate as compared with control mice (Figure 4, A and B, and our unpubcoupled receptor 43 (18), enhancing the antibacterial activity of neutrophils via NOD1 (19), priming inflammasome acti…”
BackgroundGut Microbial Metabolites Fuel Host Antibody Responses
Kim, M., Qie, Y., Park, J., & Kim, C. H. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.07.001 · Cited by 893 · cited 1×
“Moreover, microbiota-derived short-chain fatty acids have recently been demonstrated to positively regulate IgA production (41, 42).”
BackgroundThe Gut Microbiota Plays a Protective Role in the Host Defence Against Pneumococcal Pneumonia
Schuijt, T. J., Lankelma, J. M., Scicluna, B. P., de Sousa e Melo, F., Roelofs, J. J. T. H., de Boer, J. D., Hoogendijk, A. J., de Beer, R., de Vos, A., Belzer, C., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309728 · Cited by 832 · cited 1×
“First, our data do not exclude the possibility that regulation of additional antimicrobial pathways known to depend on microbiota signals (17, 19, 20, 50) might also play a role.”
BackgroundIgA Response to Symbiotic Bacteria as a Mediator of Gut Homeostasis
Peterson, D. A., McNulty, N. P., Guruge, J. L., & Gordon, J. I. (2007) · Cell Host & Microbe · doi:10.1016/j.chom.2007.09.013 · Cited by 828
Dickson, R. P., Singer, B. H., Newstead, M. W., Falkowski, N. R., Erb-Downward, J. R., Standiford, T. J., & Huffnagle, G. B. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.113 · Cited by 724
Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut
Suzuki, K., Meek, B., Doi, Y., Muramatsu, M., Chiba, T., Honjo, T., & Fagarasan, S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307317101 · Cited by 721
Jones, R. N. (2010) · Clinical Infectious Diseases · doi:10.1086/653053 · Cited by 716
New concepts in the generation and functions of IgA
Pabst, O. (2012) · Nature reviews. Immunology · doi:10.1038/nri3322 · Cited by 656 · cited 1×
“Production of high-affinity and antigen-specific IgA in Peyer’s patches and mesentery lymph nodes has further been shown to be T cell dependent (43), whereas low-affinity polyreactive IgA responses were mainly induced in isolated lymphoid follicles and subepithelial B cells in a T cell–independent manner (44).”
BackgroundGanal, S. C., Sanos, S. L., Kallfass, C., Oberle, K., Johner, C., Kirschning, C., Lienenklaus, S., Weiss, S., Staeheli, P., Aichele, P., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.05.020 · Cited by 484
Self-citationZeng, M. Y., Cisalpino, D., Varadarajan, S., Hellman, J., Warren, H. S., Cascalho, M., Inohara, N., & Núñez, G. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.006 · Cited by 417 · cited 1×
“aeruginosa infection (26), we next analyzed production of immunoglobulins.”
BackgroundTLR13 Recognizes Bacterial 23 S rRNA Devoid of Erythromycin Resistance–Forming Modification
Oldenburg, M., Krüger, A., Ferstl, R., Kaufmann, A., Nees, G., Sigmund, A., Bathke, B., Lauterbach, H., Suter, M., Dreher, S., et al. (2012) · Science · doi:10.1126/science.1220363 · Cited by 405
The essential role of the intestinal microbiota in facilitating acute inflammatory responses
Souza, D. G., Vieira, A. T., Soares, A. C., Pinho, V., Nicoli, J. R., Vieira, L. Q., & Teixeira, M. M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.4137 · Cited by 247 · cited 4×
“First, our data do not exclude the possibility that regulation of additional antimicrobial pathways known to depend on microbiota signals (17, 19, 20, 50) might also play a role.”
BackgroundInfluential
Cited by
Enaud, R., Prevel, R., Ciarlo, E., Beaufils, F., Wieërs, G., Guery, B., & Delhaes, L. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00009 · Cited by 738
Kennedy, E. A., King, K. Y., & Baldridge, M. T. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01534 · Cited by 602
Functional effects of the microbiota in chronic respiratory disease
Budden, K. F., Shukla, S. D., Rehman, S. F., Bowerman, K. L., Keely, S., Hugenholtz, P., Armstrong-James, D. P. H., Adcock, I. M., Chotirmall, S. H., Chung, K. F., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30510-1 · Cited by 446
The role of the lung microbiota and the gut–lung axis in respiratory infectious diseases
Dumas, A., Bernard, L., Poquet, Y., Lugo-Villarino, G., & Neyrolles, O. (2018) · Cellular Microbiology · doi:10.1111/cmi.12966 · Cited by 444
The role of the microbiota in infectious diseases
Libertucci, J., & Young, V. B. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0278-4 · Cited by 357
Metadata
- Authors
- Robak, O. H., Heimesaat, M. M., Kruglov, A. A., Prepens, S., Ninnemann, J., Gutbier, B., Reppe, K., Hochrein, H., Suter, M., Kirschning, C. J., Marathe, V., Buer, J., Hornef, M. W., Schnare, M., Schneider, P., Witzenrath, M., Bereswill, S., Steinhoff, U., Suttorp, N., Sander, L. E., Chaput, C., & Opitz, B.
- Venue
- Journal of Clinical Investigation
- Published
- 2018-07-16
- Volume
- 128
- Issue
- 8
- Pages
- 3535-3545
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2803953825
- Cited by
- 105
- References
- 21
- FWCI
- 10.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.